cisplatin, nivolumab
Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
Bristol Myers Squibb, CHECKMATE-648, esophageal squamous cell carcinoma, NCT03143153, nivolumab, Opdivo, Yervoy
Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy is approved by FDA for first-line esophageal squamous cell carcinoma indications
June 2022: For the first-line therapy of individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), the Food and Drug Administration has approved the following:In combination with fluoropyrimidine- and pla..
BMS, CHECKMATE-816, nivolumab, NSCLC, Opdivo
Neoadjuvant nivolumab and platinum-doublet chemotherapy is approved for early-stage non-small cell lung cancer
March 2022: In the neoadjuvant setting, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC).Thi..
Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Stivarga, Tecentriq
Drugs approved for treatment of liver cancer
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..
Bristol Myers Squibb, CHECKMATE-274, nivolumab, Opdivo, Urothelial carcinoma
Nivolumab has been approved by the FDA for use as an adjuvant treatment for urothelial carcinoma
August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence following rad..
Bristol Myers Squibb, CHECKMATE-649, fluoropyrimidine, nivolumab, Opdivo, platinum-containing chemotherapy
Nivolumab in addition to chemotherapy is approved by FDA for metastatic gastric cancer and esophageal adenocarcinoma
August 2021: For advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction wit..